Clinical Trials in Tennessee

Showing 7501-7520 of 20,239 trials

A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors

NCT05071183

A Phase 1b/2 Study of Repotrectinib in Combination with Other Anticancer Therapies for the Treatment of Subjects with KRAS-Mutant Advanced Solid Tumors (TRIDENT-2)

KRAS Mutation-Related TumorsMetastatic Solid TumorAdvanced Solid Tumor

Turning Point Therapeutics, Inc.9 participantsStarted Sep 2021

California City, California, United States • California City, California, United States • Denver, Colorado, United States +3 more locations

COMPLETEDPhase 229 miles

Study With Seletracetam (Ucb 44212) in Adult Subjects (18 to 65 Years) With Partial Onset Seizures

NCT00152451

This trial will evaluate the efficacy and safety of ucb 44212 as add on therapy in subjects with focal epilepsy.

Epilepsy, Partial

UCB S.A. - Pharma Sector31 participantsStarted May 2005

Little Rock, Arkansas, United States • San Francisco, California, United States • Stanford, California, United States +4 more locations

COMPLETEDPhase 329 miles

A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer

NCT04177108

This study evaluated the efficacy and safety of ipatasertib in combination with atezolizumab and paclitaxel in locally advanced or metastatic Triple-Negative Breast Cancer (TNBC) previously untreated in this setting.

Triple-Negative Breast Cancer

Hoffmann-La Roche242 participantsStarted Nov 2019

Mobile, Alabama, United States • Springdale, Arkansas, United States • Los Angeles, California, United States +179 more locations

A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors

Study With Seletracetam (Ucb 44212) in Adult Subjects (18 to 65 Years) With Partial Onset Seizures

A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer

Find Trials by Condition in Tennessee

A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)

Multiple Cardiac Sensors for the Management of Heart Failure

Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat in Non-Dialysis Subjects Evaluating Hemoglobin (Hgb) and Quality of Life (ASCEND-NHQ)

A Study to Evaluate the Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of TAK-079 in Combination With Standard Background Therapy in Participants With Moderate to Severe Systemic Lupus Erythematosus (SLE)

A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies

Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors

A Study of Mirikizumab (LY3074828) in Children and Teenagers With Ulcerative Colitis (UC)

A Study to Evaluate the Pharmacodynamic (PD) Effects of Once Weekly Administration of Gantenerumab in Participants With Early Alzheimer's Disease (AD)

Critical Illness Myopathy and Trajectory of Recovery in AKI Requiring CRRT

Evaluation of S-600918 in Adults With Refractory Chronic Cough

Efficacy and Safety of CBP-201 in Patients With Moderate to Severe Persistent Asthma With Type 2 Inflammation

Effect of CREON on Exocrine Pancreatic Insufficiency (EPI) Symptoms

Study of Magrolimab (Hu5F9-G4) in Combination With Avelumab in Solid Tumor Participants and Checkpoint-Inhibitor-Naive Ovarian Cancer Participants Who Progress Within 6 Months of Prior Platinum Chemotherapy

A Study Of Avelumab In Patients With Locally Advanced Or Metastatic Urothelial Cancer (JAVELIN Bladder 100)

A Study of Pirtobrutinib (LY3527727 [LOXO-305]) Versus Placebo in Participants With Relapsing Multiple Sclerosis

Pilot Study of Nivolumab in Pediatric Patients With Hypermutant Cancers

Safety of Ruconest in 2-13 Year Old Hereditary Angioedema (HAE) Patients